Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Level BiotechnologyROCO:3118 -0.63%75 5-Year Yield-on-Cost % is 8.91 as of Aug. 23, 2026, which is 26% above its 10-year median of 7.05. GuruFocus rates ROCO:3118 with a GF Score™ of 75/100 and a GF Value™ of NT$32.88 (Fairly Valued). The stock has 2 warning signs investors should review. Among 150 Biotechnology companies, Level Biotechnology ranks better than 91.33% on this metric.
Level Biotechnology's yield on cost for the quarter that ended in Jun. 2026 was 8.91.
The historical rank and industry rank for Level Biotechnology's 5-Year Yield-on-Cost % or its related term are showing as below:
ROCO:3118'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 3.37 Med: 7.05 Max: 17.01
Current: 8.91
During the past 13 years, Level Biotechnology's highest Yield on Cost was 17.01. The lowest was 3.37. And the median was 7.05.
ROCO:3118's 5-Year Yield-on-Cost % is ranked better than 91.33% of 150
companies
in the Biotechnology industry
Industry Median: 1.65
vs ROCO:3118: 8.91
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Level Biotechnology 5-Year Yield-on-Cost % Related Terms
ROCO:3118 vs VRTX, REGN, RVMD: 5-Year Yield-on-Cost % Comparison
For the Biotechnology subindustry, Level Biotechnology's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Level Biotechnology 5-Year Yield-on-Cost % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Level Biotechnology's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Level Biotechnology's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Level Biotechnology (ROCO:3118) has a 5-Year Yield-on-Cost % of 8.91 as of Aug. 23, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Level Biotechnology and its competitors. This is 26% above median its historical median of 7.05. Over the past decade, Level Biotechnology's 5-Year Yield-on-Cost % has ranged from 3.37 to 17.01. According to the industry distribution chart, Level Biotechnology ranks #13 out of 150 companies in the Biotechnology industry, placing it in the top 8.7%.
Is Level Biotechnology's 5-Year Yield-on-Cost % too high?
Level Biotechnology's current 5-Year Yield-on-Cost % of 8.91 is 26% above median its 10-year median of 7.05. Over the past 10 years, this metric has ranged from a low of 3.37 to a high of 17.01. The Biotechnology industry median 5-Year Yield-on-Cost % is 1.65. Level Biotechnology's value of 8.91 is 440% above this industry median. Based on the distribution chart, Level Biotechnology ranks #13 out of 150 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Level Biotechnology has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Level Biotechnology's 5-Year Yield-on-Cost % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Level Biotechnology ranks #13 out of 150 companies for 5-Year Yield-on-Cost %. This places Level Biotechnology in the top 9% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 1.65. Level Biotechnology's value of 8.91 is 440% above this benchmark. Historically, Level Biotechnology's own 5-Year Yield-on-Cost % has ranged from 3.37 to 17.01 over the past decade. While the company's 10-year median is 7.05 vs. the industry median of 1.65, Level Biotechnology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.65, based on 150 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Level Biotechnology's current 5-Year Yield-on-Cost % of 8.91 is 440% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Level Biotechnology and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Level Biotechnology's current 5-Year Yield-on-Cost % is 8.91, which is 26% above median its own 10-year median of 7.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Level Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Level Biotechnology (ROCO:3118) is currently considered Fairly Valued. The stock's GF Value™ is NT$32.88, compared to a current price of NT$31.50 — trading 4.2% below its estimated fair value. The current 5-Year Yield-on-Cost % is 8.91, which is 26% above median its 10-year median of 7.05 and 440% above the Biotechnology industry median of 1.65. Level Biotechnology's overall GF Score™ is 75/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Level Biotechnology (ROCO:3118), the current 5-Year Yield-on-Cost % is 8.91 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Level Biotechnology (ROCO:3118) Overvalued in 2026?
Based on GuruFocus' analysis, Level Biotechnology stock appears to be undervalued.
The current stock price of NT$31.50 is trading 4.2% below its estimated GF Value™ of NT$32.88.
GuruFocus considers Level Biotechnology to be Fairly Valued.
Key valuation signals for ROCO:3118:
5-Year Yield-on-Cost %: 8.91 (26% above median its 10-year median of 7.05)
GF Value™: NT$32.88 vs. price of NT$31.50 (4.2% below fair value)
Industry Position: 440% above the Biotechnology median (#13 of 150)
No single metric tells the full story. See the ROCO:3118 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Level Biotechnology Inc is a Taiwan-based company engaged in the sales of biomedical products and providing preclinical testing services. The company has three reportable segments: Department A and B, Department C, and Department D. Department A and Department B sell the cell culture consumables and the antibody reagents, Department C sells the instruments and equipment, and Department D provides CRO services. The majority of revenue is derived from the Department A and B.
75GF Score
Get the complete analysis for ROCO:3118
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:3118 has been successfully added to your 
